The VE-BASKET trial (an open-label non-randomized trial assessing the BRAF inhibitor vemurafenib in BRAF V600-mutated non-melanoma cancers) reported an objective response rate of 25% across all gliomas studied (6). This evidence concerns the gene BRAF and melanoma.